Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Chemistry & Biodiversity|February 27, 2025
Integrated Computational and Experimental Insights Into MEK1/2 Inhibitors: Structural Validation, Docking, ADMET, Molecular Dynamics, and Anticancer EvaluationRohit Pal, Gurubasavaraja Swamy Purawarga Matada, Ghanshyam Teli
European Journal of Medicinal Chemistry|July 8, 2023
The role of natural anti-parasitic guided development of synthetic drugs for leishmaniasisRohit Pal, Ghanshyam Teli, Md Jawaid Akhtar, et al.
Bioorganic Chemistry|August 21, 2024
Therapeutic potential of anticancer activity of nitrogen-containing heterocyclic scaffolds as Janus kinase (JAK) inhibitor: Biological activity, selectivity, and structure-activity relationshipRohit Pal, Gurubasavaraja Swamy Purawarga Matada, Ghanshyam Teli, et al.
European Journal of Medicinal Chemistry|November 17, 2023
Synthetic product-based approach toward potential antileishmanial drug developmentRohit Pal, Ghanshyam Teli, Md Jawaid Akhtar, et al.
Journal of Biomolecular Structure & Dynamics|August 29, 2023
An outlook of docking analysis and structure-activity relationship of pyrimidine-based analogues as EGFR inhibitors against non-small cell lung cancer (NSCLC)Rohit Pal, Ghanshyam Teli, Sindhuja Sengupta, et al.
Chemistry & Biodiversity|April 19, 2025
Design, Synthesis, and Molecular Profiling of Pyrimidine-Furan Derivatives Targeting EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S in NSCLC: In Vitro and In Silico EvaluationRohit Pal, Gurubasavaraja Swamy Purawarga Matada, Ghanshyam Teli, et al.
Journal of Biomolecular Structure & Dynamics|May 5, 2023
Explanatory review on pyrimidine/fused pyrimidine derivatives as anticancer agents targeting Src kinaseGhanshyam Teli, Rohit Pal, Lalmohan Maji, et al.
Molecular Diversity|June 19, 2026
Pyrimidine derivatives as anticancer agents targeting kinases: design strategies, biological evaluation, and structure-activity relationship insightsManjushree Bv, Gurubasavaraja Swamy Purawarga Matada, Rohit Pal, et al.
Drug Discovery Today|June 22, 2025
Exploring nucleotide and non-nucleotide cGAS-STING agonists: Therapeutic applications and future directions in cancer immunotherapyAbhishek Ghara, Gurubasavaraja Swamy Purawarga Matada, Payel Pramanick, et al.
Bioimpacts : BI|April 21, 2025
In-silico based discovery of potential Keap1 inhibitors using the strategies of pharmacophore screening, molecular docking, and MD simulation studiesEkta Singh, Gurubasavaraja Swamy Purawarga Matada, Prasad Sanjay Dhiwar, et al.
Pageof 3